All In Biotech

Drug Trial Radar · NCT07748702

Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers

An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Pharmacokinetics and the Safety of D311 and D107 Compared to CKD-339 in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

Sep 19, 2026

Primary completion

Oct 7, 2026

Study completion Oct 29, 2026

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-339 in healthy volunteers.

Conditions

  • Hypertension

Interventions

  • CKD-339Drug

    QD, PO

  • D311, D107Drug

    QD, PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCt of CKD-339Time frame: From 0 to 72 hours postdose
  2. Cmax of CKD-339Time frame: From 0 to 72 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bumin Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.